Virtus Biotech ETF (BBP) is recommended as a buy due to its focused investment in FDA-approved biotech companies and strong recent performance. The ETF uses an equal-weight, quarterly rebalancing strategy that captures gains from breakout stocks like Moderna (MRNA) while managing speculative risks. Growth in biotech sector deals and expansion in the GLP-1 market support a positive outlook for BBP despite challenges like rising interest rates. Its concentrated portfolio, which does not pay dividends, offers cost efficiency and resilience compared to larger biotech ETFs, making it attractive for long-term investors.
Hedge funds have been steadily buying Pfizer shares, attracted by its 6.3% dividend yield and promising oncology drug pipeline. Despite challenges from upcoming patent expirations that could impact earnings, Pfizer's late-stage cancer treatments and ...
Moderna's stock surged 176.9% to $174.38 on August 19, 2026, boosting its market cap to about $69.6 billion. The company expects to end 2026 with $4.7-$5.2 billion in cash and investments, plus a $0.9 billion credit line. CEO Stéphane Bancel highligh...
Morgan Stanley upgraded Merck to Overweight with a $179 price target, citing a 17.6% upside following successful Phase 3 results of Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda. The vaccine showed significant improvemen...
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...
Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...
